Dedicated to developing novel antipsychotics with additional efficacy in depression, anxiety, and cognitive dysfunction. She uses behavioral, biochemical, and molecular approaches to uncover receptor-based mechanisms, with further expertise in cardiovascular and safety pharmacology.

Focused on neurobiological mechanisms regulating cognition, she studies G protein–coupled receptor signaling, particularly dopaminergic D₂ and serotonergic 5-HT_1A pathways, to reveal how receptor-specific mechanisms shape memory and guide the search for new therapeutic target.

Investigates novel compounds with antipsychotic and cognition-enhancing properties, potentially extending to antidepressant and anxiolytic effects. She uses behavioral models and molecular analyses to study cognitive and emotional functions relevant to schizophrenia.

Explores how novel compounds affect executive functions and cognition. Her research combines touchscreen-based behavioral testing with molecular approaches and FRET-based fiber photometry to uncover how pharmacological modulation shapes cognitive performance and neuronal activity.

Investigates sex-related differences in behavioral and molecular responses to pharmacological treatments and their effects on cognitive processes in health and affective disorders, combining behavioral analyses with experimental approaches to reveal underlying mechanisms and translational relevance.